Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2017 Mar 18

PMID 28303448

Citations 38

Authors

Benjamin Z Leder

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The purpose is to review the efficacy and optimal use of parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis treatment.

Recent Findings: The parathyroid hormone analog teriparatide, a potent stimulator of bone remodeling, increases hip and spine bone mineral density and reduces the risk of vertebral and non-vertebral fractures in postmenopausal osteoporotic women. The parathyroid hormone-related protein analog, abaloparatide, also reduces fracture incidence but has pharmacological effects that differ from teriparatide, particularly in cortical bone. These analogs provide maximal benefit when their use is followed by a potent antiresorptive medication. Moreover, studies have shown that the combination of teriparatide and the RANK-ligand inhibitor, denosumab, increase bone density and estimated strength more than monotherapy and more than any currently available regimen. Parathyroid hormone and parathyroid hormone-related protein analogs, whether as monotherapy, in combination with antiresorptive agents or in sequence with antiresorptive agents, will likely play an expanding role in osteoporosis management.

Citing Articles

A Real-Life Study in Sequential Therapy for Severe Menopausal Osteoporosis.

Sima O, Costachescu M, Stanciu M, Nistor C, Carsote M, Tanasescu D J Clin Med. 2025; 14(2).

PMID: 39860632 PMC: 11766421. DOI: 10.3390/jcm14020627.

Apoptotic vesicles rescue impaired mesenchymal stem cells and their therapeutic capacity for osteoporosis by restoring miR-145a-5p deficiency.

Zhang R, Mu X, Liu D, Chen C, Meng B, Qu Y J Nanobiotechnology. 2024; 22(1):580.

PMID: 39304875 PMC: 11414301. DOI: 10.1186/s12951-024-02829-2.

Zhang Y, Yan J, Zhang Y, Liu H, Han B, Li W Int J Oral Sci. 2024; 16(1):52.

PMID: 39085217 PMC: 11291511. DOI: 10.1038/s41368-024-00319-7.

Low bone mineral density: a primer for the spine surgeon.

Raad M, Kim A, Durand W, Kebaish K Spine Deform. 2024; 12(6):1511-1520.

PMID: 39060777 DOI: 10.1007/s43390-024-00913-z.

Apoptotic vesicles rescue impaired mesenchymal stem cells and their therapeutic capacity for osteoporosis by restoring miR-145a-5p deficiency.

Zhang R, Mu X, Liu D, Chen C, Meng B, Qu Y Res Sq. 2024; .

PMID: 38883762 PMC: 11177995. DOI: 10.21203/rs.3.rs-4416138/v1.

References

Kaufman J, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky G . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2004; 16(5):510-6. DOI: 10.1007/s00198-004-1713-3. View

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster D, Hodsman A . Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22(4):495-502. DOI: 10.1359/jbmr.070104. View

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E . Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20(9):1507-13. DOI: 10.1359/JBMR.050501. View

Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W . Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study. J Bone Miner Res. 2014; 29(8):1777-85. DOI: 10.1002/jbmr.2216. View

Rittmaster R, Bolognese M, Ettinger M, Hanley D, Hodsman A, Kendler D . Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85(6):2129-34. DOI: 10.1210/jcem.85.6.6614. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

Deal C, Omizo M, Schwartz E, Eriksen E, Cantor P, Wang J . Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005; 20(11):1905-11. DOI: 10.1359/JBMR.050714. View

Finkelstein J, Hayes A, Hunzelman J, Wyland J, Lee H, Neer R . The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349(13):1216-26. DOI: 10.1056/NEJMoa035725. View

10.

Polyzos S, Makras P, Efstathiadou Z, Anastasilakis A . Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opin Investig Drugs. 2014; 24(2):145-57. DOI: 10.1517/13543784.2015.973021. View

11.

Cosman F, Eriksen E, Recknor C, Miller P, Guanabens N, Kasperk C . Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):503-11. DOI: 10.1002/jbmr.238. View

12.

Reeve J, Bradbeer J, Arlot M, Davies U, Green J, Hampton L . hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int. 1991; 1(3):162-70. DOI: 10.1007/BF01625448. View

13.

Popp A, Zysset P, Lippuner K . Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2015; 27(5):1917-21. DOI: 10.1007/s00198-015-3458-6. View

14.

Dempster D, Cosman F, Kurland E, Zhou H, Nieves J, Woelfert L . Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16(10):1846-53. DOI: 10.1359/jbmr.2001.16.10.1846. View

15.

Schafer A, Sellmeyer D, Palermo L, Hietpas J, Eastell R, Shoback D . Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012; 97(10):3522-9. PMC: 3674294. DOI: 10.1210/jc.2012-1844. View

16.

Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V . Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16(5):925-31. DOI: 10.1359/jbmr.2001.16.5.925. View

17.

Reeve J, Arlot M, Bradbeer J, Hesp R, Mcally E, Meunier P . Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int. 1993; 3 Suppl 1:199-203. DOI: 10.1007/BF01621906. View

18.

Miller P, Hattersley G, Riis B, Williams G, Lau E, Russo L . Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016; 316(7):722-33. DOI: 10.1001/jama.2016.11136. View

19.

Leder B, ODea L, Zanchetta J, Kumar P, Banks K, McKay K . Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2014; 100(2):697-706. DOI: 10.1210/jc.2014-3718. View

20.

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M . Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012; 97(9):3097-106. DOI: 10.1210/jc.2011-3479. View